Related Experiment Video

Updated: Aug 14, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Hepatitis B and C in children: current treatment and future strategies

Scott A Elisofon1, Maureen M Jonas

  • 1Division of Gastroenterology, Children's Hospital Boston, Hunnewell Ground, 300 Longwood Avenue, Boston, MA 02115, USA.

Clinics in Liver Disease
|December 27, 2005
PubMed

Insights

Chronic hepatitis B (HBV) and hepatitis C (HCV) infections in children require better treatment strategies. This review details differences in pediatric viral hepatitis and explores current and future treatment options for children.

Area of Science:

  • Pediatric Hepatology
  • Viral Hepatitis Research
  • Infectious Diseases in Children

Background:

  • Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are often acquired in childhood.
  • While less common than in adults, childhood HCV infections are a significant global health concern.
  • Limited data on the natural history and few approved medications hinder optimal pediatric treatment.

Purpose of the Study:

  • To compare chronic viral hepatitis in children versus adults regarding epidemiology, natural history, disease progression, and treatment response.
  • To review current and emerging treatment options for chronic HBV and HCV in pediatric populations.
  • To highlight the need for further research and development of pediatric-specific therapies.

Main Methods:

  • Literature review and synthesis of existing data on pediatric viral hepatitis.
  • Comparative analysis of epidemiological and clinical characteristics in children and adults.
  • Examination of current treatment guidelines and ongoing clinical trials for pediatric HBV and HCV.

Main Results:

  • Chronic viral hepatitis presents distinct epidemiological and clinical patterns in children compared to adults.
  • Significant gaps exist in understanding the long-term outcomes of childhood HBV and HCV infections.
  • Current treatment options for pediatric viral hepatitis are limited, with few approved antiviral medications.

Conclusions:

  • Optimizing treatment for chronic HBV and HCV in children necessitates a deeper understanding of disease natural history.
  • Development of age-appropriate medications and treatment protocols is crucial for improving pediatric outcomes.
  • Further research and clinical studies are essential to establish effective, evidence-based strategies for managing childhood viral hepatitis.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...